Stock CYN CLEARMIND MEDICINE INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Clearmind Medicine Inc. Canadian Securities Exchange

Equities

CYN

CA1850534027

Delayed Canadian Securities Exchange
Other stock markets
 		5-day change 1st Jan Change
- CAD -.--% Intraday chart for Clearmind Medicine Inc. -13.51% -58.01%
Jul. 16 Top Midday Decliners MT
Jul. 16 Clearmind Medicine Inc. Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Top Midday Decliners
MT
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
AQ
Clearmind Medicine Inc. Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
CI
SciSparc Seeks Patent for Obesity Drug Ingredient's Composition
MT
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
AQ
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
CI
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine, Israel 2024 Conference
AQ
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
AQ
Clearmind Medicine Inc. Announces Advancement in its Proprietary MEAI- Based Binge Behaviors Treatment
CI
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
AQ
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
AQ
Clearmind Medicine Secures Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
CI
Clearmind Medicine Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024
CI
Clearmind Medicine : Condensed Interim Consolidated Financial Statements Form 6 K
PU
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
AQ
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
AQ
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
AQ
Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
CI
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
AQ
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMND Stock
  4. CYN Stock
  5. News Clearmind Medicine Inc.